ICER’s Revised Value Assessment Framework for 2017–2019: A Critique

This is a preview of subscription content, log in to check access.


  1. 1.

    Institute for Clinical and Economic Review. Overview of the ICER assessment framework and update for 2017–2019. Accessed 24 Jul 2017.

  2. 2.

    Neumann PJ, Sanders GD, Russell LB, Siegel JE, Ganiats TG, editors. Cost-effectiveness in health and medicine. 2nd ed. New York: Oxford University Press; 2016.

    Google Scholar 

  3. 3.

    Lakdawalla D, Neumann PJ. Budget criteria and drug value assessments: a case of apples and oranges? Health Affairs Blog. 22 Sep 2015. Accessed 24 Jul 2017.

  4. 4.

    Neumann PJ, Cohen JT. Measuring the value of prescription drugs. N Engl J Med. 2015;373:2595–7.

    Article  PubMed  Google Scholar 

Download references

Author information



Corresponding author

Correspondence to Peter J. Neumann.

Ethics declarations


No funding was received for this commentary.

Conflicts of interest

The Center for the Evaluation of Value and Risk in Health at Tufts Medical Center receives funding from numerous government, non-profit foundation, and pharmaceutical industry sources. Both Drs Neumann and Cohen have frequently consulted with the pharmaceutical industry and serve as consultants to Precision Health Economics.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Neumann, P.J., Cohen, J.T. ICER’s Revised Value Assessment Framework for 2017–2019: A Critique. PharmacoEconomics 35, 977–980 (2017).

Download citation